Taking the Next Step Semaglutide offers men a highly effective tool for addressing obesity and its numerous associated health consequences
1) Moreover, several large, prospective, randomized studies have been developed to investigate the association between GLP-1 RAs intake in DM 2 patients and a known cardiovascular disease (CVD) or high cardiovascular (CV) risk
As we reported here, on September 16, 2025, FDA published over 55 warning letters to online sellers of compounded versions of GLP-1, the popular weight-loss injections marketed as Wegovy (semaglutide injection, manufactured by Novo Nordisk) and Zepbound (tirzepatide injection, manufactured by Eli Lilly)
Cavalheiro EA, Lehmann J, Turski L, editors
Both surgery and GLP-1s are part of a continuum of treatments for obesity